GNI Group

GNI Group is a global multinational company listed and incorporated in Japan, engaged in the research, development, manufacturing, and sales of pharmaceuticals and traditional Chinese medicine. The company focuses on the development of therapeutic drugs, including F647 for the treatment of radiation pneumonia and idiopathic pulmonary fibrosis, F351 for liver fibrosis, and F573 for acute liver failure and acute-on-chronic liver failure.